We have observed
4 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 publication dated after February 18, 2013).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
ORAL DOSAGE FORMS OF BENDAMUSTINE
ORAL DOSAGE FORMS OF BENDAMUSTINE AND THERAPEUTIC USE THEREOF
COMPOSITION OF TIACUMICIN COMPOUNDS
SYSTEM AND METHOD FOR ANALYZING ADVERSE EVENT DATA